Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Psoriasis

    Tag: Psoriasis

    You Searched For "Psoriasis"
    Sun Pharma to ramp up global speciality business; eyes "low-to-mid teens" growth in revenues for FY20

    Sun Pharma to ramp up global speciality business; eyes "low-to-mid teens" growth in revenues for FY20

    Medical Dialogues Bureau1 Aug 2019 4:30 AM GMT
    The company is targeting key ailments like psoriasis to gradually ramp up its global speciality business, Dilip Shanghvi said adding that Sun Pharma...
    Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

    Sun Pharma enters licensing agreement with CMS for arthritis drug Tildrakizumab

    Medical Dialogues Bureau28 Jun 2019 7:00 AM GMT
    The initial tenure of the agreement between Sun Pharma and CMS shall be 15 years from the first commercial sale of Tildrakizumab in Greater China and...
    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Medical Dialogues Bureau26 Jun 2019 3:30 AM GMT
    Bristol-Myers announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology...
    Dr Reddys yields positive results from phase 2b study of new psoriasis drug

    Dr Reddys yields positive results from phase 2b study of new psoriasis drug

    Farhat Nasim10 Jun 2019 8:32 AM GMT
    The detailed safety and efficacy data from the study would be presented in future dermatology conferences, reads Dr Reddy's (Dr Reddys) recent...
    Novartis sees 2019 growth as it sheds eyecare unit, narrows focus

    Novartis sees 2019 growth as it sheds eyecare unit, narrows focus

    Garima30 Jan 2019 3:30 AM GMT
    Novartis said sales of its Entresto heart failure medicine accelerated along with revenue from its psoriasis-and-arthritis blockbuster...
    Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

    Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

    Ruby Khatun Khatun21 Sep 2017 4:27 AM GMT
    Basel, September 13, 2017 - Novartis announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X